Don't Miss These Facts About Moderna

By Kim Brooks • Friday, December 15 14:15 • Permanent Link

Large-cap Health Care company Moderna has moved 0.6% so far today on a volume of 5,308,158, compared to its average of 4,361,900. In contrast, the S&P 500 index moved -0.0%.

Moderna trades -33.28% away from its average analyst target price of $129.53 per share. The 19 analysts following the stock have set target prices ranging from $52.0 to $300.0, and on average have given Moderna a rating of hold.

Anyone interested in buying MRNA should be aware of the facts below:

Moderna has moved -55.6% over the last year, and the S&P 500 logged a change of 22.5%
Based on its trailing earnings per share of -9.23, Moderna has a trailing 12 month Price to Earnings (P/E) ratio of -9.4 while the S&P 500 average is 15.97
MRNA has a forward P/E ratio of -12.8 based on its forward 12 month price to earnings (EPS) of $-6.74 per share
The company has a price to earnings growth (PEG) ratio of 0.12 — a number near or below 1 signifying that Moderna is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 2.45 compared to its sector average of 4.08
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally.
Based in Cambridge, the company has 3,900 full time employees and a market cap of $32.95 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.